Investors Who Bought GLG Pharma (WSE:GLG) Shares A Year Ago Are Now Down 76%

It’s not a secret that every investor will make bad investments, from time to time. But it should be a priority to avoid stomach churning catastrophes, wherever possible. So we hope that those who held GLG Pharma S.A. (WSE:GLG) during the last year don’t lose the lesson, in addition to the 76% hit to the value of their shares. That’d be enough to make even the strongest stomachs churn. Notably, shareholders had a tough run over the longer term, too, with a drop of 48% in the last three years. Shareholders have had an even rougher run lately, with the share price down 22% in the last 90 days.

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

View our latest analysis for GLG Pharma

With zero revenue generated over twelve months, we don’t think that GLG Pharma has proved its business plan yet. We can’t help wondering why it’s publicly listed so early in its journey. Are venture capitalists not interested? So it seems that the investors focused more on what could be, than paying attention to the current revenues (or lack thereof). Investors will be hoping that GLG Pharma can make progress and gain better traction for the business, before it runs low on cash.

Companies that lack both meaningful revenue and profits are usually considered high risk. You should be aware that there is always a chance that this sort of company will need to issue more shares to raise money to continue pursuing its business plan. While some such companies do very well over the long term, others become hyped up by promoters before eventually falling back down to earth, and going bankrupt (or being recapitalized). It certainly is a dangerous place to invest, as GLG Pharma investors might realise.

Our data indicates that GLG Pharma had zł3,149,975 more in total liabilities than it had cash, when it last reported in December 2018. That puts it in the highest risk category, according to our analysis. But with the share price diving 76% in the last year, it’s probably fair to say that some shareholders no longer believe the company will succeed. The image below shows how GLG Pharma’s balance sheet has changed over time; if you want to see the precise values, simply click on the image.

WSE:GLG Historical Debt, May 24th 2019
WSE:GLG Historical Debt, May 24th 2019

Of course, the truth is that it is hard to value companies without much revenue or profit. Would it bother you if insiders were selling the stock? I’d like that just about as much as I like to drink milk and fruit juice mixed together. It only takes a moment for you to check whether we have identified any insider sales recently.

A Different Perspective

While the broader market lost about 4.3% in the twelve months, GLG Pharma shareholders did even worse, losing 76%. Having said that, it’s inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Unfortunately, last year’s performance may indicate unresolved challenges, given that it was worse than the annualised loss of 17% over the last half decade. We realise that Buffett has said investors should ‘buy when there is blood on the streets’, but we caution that investors should first be sure they are buying a high quality businesses. You could get a better understanding of GLG Pharma’s growth by checking out this more detailed historical graph of earnings, revenue and cash flow.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on PL exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.